Active Pharmaceutical Ingredients
Therapeutic Area Products Status
Anti-Cancer Irinotecan hydrochloride USP USDMF No. 30516
Anti-Cancer Lenalidomide Open part DMF
Anti-Ulcer Misoprostol 1% dispersion in HPMC Tech pack
Anti Thrombotic Ticagrelor COA and samples
Ophthalmic Travoprost COA and samples
Anti-Cancer Topotecan hydrochloride COA and samples
Anti-Cancer Abiraterone Acetate COA and samples
Anti-Cancer Pazopanib R&D Development
Anti-Cancer Palbociclib R&D Development
Anti-Cancer Carfilzomib R&D Development
Anti-Cancer Regorafenib R&D Development
Hematology Eltrombopag R&D Development
PAH Macitentan R&D Development
Abortifacient Mifepristone R&D Development
Anti Coagulant Apixaban R&D Development
Antipsychotic Pimavanserin R&D Development
Name CAS No.
Irinotecan Intermediates
7-Ethyl-10-hydroxycamptothecin (SN-38) (USDMF No. 27429) 86639-52-3
(s)-8-Ethyl-8-hydroxy-2,3,5,8-tetrahydro-6-oxa-3a-aza-cyclopenta [b]naphthalene-1,4,7-trione 110351-94-5
2-Amino-5-hydroxypropiophenone (AHPP) 35364-15-9
Topotecan – Intermediates
10-hydroxycamptothecin (USDMF No. 26025) 19685-09-07
Travoprost Intermediates
Dimethyl [2-oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonate 54094-19-8
(+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one 53872-60-9
Other Intermediates
Camptothecin 7689-03-4
7-Ethylcamptothecin 78287-27-1
Olivetol 500-66-3
Ethyl olivetolate 38862-65-6
2,4-dichloropyrimidine 3934-20-1
3-Oxocyclobutanecarboxylic acid 23761-23-1
6-Hydroxy-1,2,3,4-tetrahydroisoquinoline 14446-24-3
2-Amino-5-bromobenzaldehyde 29124-57-0
2,6-Dimethylmorpholine 141-91-3
Quinoxaline-2-carboxaldehyde 1593-08-4
2-Chloro-1,3,2-dioxaphospholane 2-oxide 6609-64-9
2-Ethylmorpholine 52769-10-5
4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 286961-14-6
Beta-glycerophosphate disodiumsalt pentahydrate 13408-09-8
trans-1-Propenylboronic acid pinacol ester 83947-58-4
Trimethylsulfoxonium chloride 5034-06-0
All transactions are carried out in conformity with patent laws applicable in the user country. Responsibility with respect to third party's patent right in a specific country lies exclusively with the buyer. Products currently covered by valid US patents are offered for R&D use in accordance with 35 USC 271 A13(1)